ABIRATERONE ACETATE (AA) plus PREDNISOLONE (P) FOR METASTATIC CASTRATION- RESISTANT PROSTATE CANCER (MCRPC) WITH EARLY PROGRESSION OR NO-RESPONSE TO ANDROGEN DEPRIVATION THERAPY (ADT); FINAL ANALYSIS

被引：0
|
作者：
Nakatsu, Hiroomi
Maniwa, Akimitsu
Kamiya, Naoto
Ogi, Mizue
Kobayashi, Hisanori
Nakayama, Masahiko
机构：
来源：
JOURNAL OF UROLOGY | 2018年 / 199卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD10-08
引用
收藏
页码：E230 / E231
页数：2
相关论文
共 50 条
  • [1] Abiraterone acetate (AA) plus prednisolone (P) for metastatic castration-resistant prostate cancer (mCRPC) with early progression or non-response to androgen deprivation therapy (ADT)
    Arai, G.
    Ogi, M.
    Kobayashi, K.
    Okuno, N.
    Takahara, T.
    Fukushima, K.
    Yoshizawa, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC).
    Jha, Gautam Gopalji
    Jeff, Engle
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Indicators of clinical response to abiraterone acetate (AA) men with metastatic castration-resistant-prostate-cancer (mCRPC).
    Boegemann, Martin
    Mikah, Phillip
    Eminaga, Okyaz
    Herrmann, Edwin
    Papavassills, Philipp Marius
    Semjonow, Axel
    Krabbe, Laura-Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Titus, Mark Anton
    Wen, Sijin
    SanMiguel, Aileen
    Hoang, Anh
    De Haas-Amatsaleh, Angela
    Perabo, Frank
    De Phung
    Troncoso, Patricia
    Ouatas, Taoufik
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.
    Francini, Edoardo
    Gray, Kathryn P.
    Evan, Carolyn
    Kaymakcalan, Marina D.
    Shaw, Grace Katherine
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Di Stefano, Rosario F.
    Tucci, Marcello
    Turco, Fabio
    Samuelly, Alessandro
    Bungaro, Maristella
    Pisano, Chiara
    Vignani, Francesca
    Gallicchio, Mara
    Scagliotti, Giorgio V.
    Di Maio, Massimo
    Buttigliero, Consuelo
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (03) : 812 - 825
  • [7] Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Rosario F. Di Stefano
    Marcello Tucci
    Fabio Turco
    Alessandro Samuelly
    Maristella Bungaro
    Chiara Pisano
    Francesca Vignani
    Mara Gallicchio
    Giorgio V. Scagliotti
    Massimo Di Maio
    Consuelo Buttigliero
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 812 - 825
  • [8] CLINICAL ACTIVITY OF ABIRATERONE ACETATE (AA) AFTER PROGRESSION ON MDV3100 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
    Noonan, K.
    Ellard, S.
    Chi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 305 - 305
  • [9] Androgen receptor (AR) based biomarker association with response to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC).
    Kohli, Manish
    Wang, Liguo
    Sicotte, Hugues
    Qin, Rui
    Carlson, Rachel
    Eckel-Passow, Jeanette
    Tan, Winston
    Wu, Kevin
    Dehm, Scott
    Eiken, Patrick W.
    Jimenez, Rafael E.
    Cernigliaro, Joseph
    Quevedo, Fernando
    Costello, Brian Addis
    Pitot, Henry Clement
    Moynihan, Timothy J.
    Ho, Thai Huu
    Dronca, Roxana Stefania
    Bryce, Alan Haruo
    Wang, Liewei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [10] Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).
    Khalaf, Daniel Joseph
    Chen, Liheng
    Sunderland, Katherine
    Vergidis, Joanna
    Noonan, Krista
    Finch, Daygen L.
    Zulfiqar, Muhammad
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345